ES2346178T3 - Nuevas composiciones, procedimientos y usos de unión de la albúmina - Google Patents

Nuevas composiciones, procedimientos y usos de unión de la albúmina Download PDF

Info

Publication number
ES2346178T3
ES2346178T3 ES08786222.3T ES08786222T ES2346178T3 ES 2346178 T3 ES2346178 T3 ES 2346178T3 ES 08786222 T ES08786222 T ES 08786222T ES 2346178 T3 ES2346178 T3 ES 2346178T3
Authority
ES
Spain
Prior art keywords
seq
albumin binding
albumin
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08786222.3T
Other languages
English (en)
Spanish (es)
Other versions
ES2346178T1 (es
Inventor
Lars Abrahmsén
Andreas Jonsson
Jakob Dogan
Per-Åke Nygren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of ES2346178T1 publication Critical patent/ES2346178T1/es
Application granted granted Critical
Publication of ES2346178T3 publication Critical patent/ES2346178T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08786222.3T 2007-07-31 2008-07-17 Nuevas composiciones, procedimientos y usos de unión de la albúmina Active ES2346178T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
US962618P 2007-07-31
EP07113533 2007-07-31
EP07113533 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Publications (2)

Publication Number Publication Date
ES2346178T1 ES2346178T1 (es) 2010-10-13
ES2346178T3 true ES2346178T3 (es) 2015-11-02

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08786222.3T Active ES2346178T3 (es) 2007-07-31 2008-07-17 Nuevas composiciones, procedimientos y usos de unión de la albúmina

Country Status (11)

Country Link
US (2) US8937153B2 (enExample)
EP (2) EP2546261A3 (enExample)
JP (1) JP5718638B2 (enExample)
CN (2) CN104710518A (enExample)
AU (1) AU2008281913B2 (enExample)
CA (1) CA2694139C (enExample)
DE (1) DE08786222T1 (enExample)
DK (1) DK2190863T3 (enExample)
ES (1) ES2346178T3 (enExample)
HK (1) HK1211040A1 (enExample)
WO (1) WO2009016043A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE08786222T1 (de) * 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
DK2977088T3 (en) * 2010-03-08 2017-10-09 Ge Healthcare Bioprocess R&D Ab IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE
WO2011136361A1 (ja) * 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
TR201809437T4 (tr) * 2010-07-09 2018-07-23 Affibody Ab Polipeptitler.
AU2011286024B2 (en) * 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012050923A2 (en) * 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
CN103547590B (zh) 2010-09-28 2017-11-28 埃格里昂制药股份有限公司 高度可溶性瘦蛋白
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
EA201391753A1 (ru) * 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
DK2729160T3 (da) * 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
EP2729481B1 (en) * 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HRP20190522T1 (hr) 2012-02-20 2019-05-03 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi koji se vežu za humani komplement c5
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
KR20140142298A (ko) 2012-03-28 2014-12-11 애피바디 에이비 경구투여
EP2855509B1 (en) 2012-05-25 2018-05-02 Janssen Biotech, Inc. Non-natural consensus albumin binding domains
CN104662035A (zh) * 2012-09-25 2015-05-27 阿菲博迪公司 白蛋白结合多肽
WO2014053586A1 (en) 2012-10-05 2014-04-10 Affibody Ab Her3 binding polypeptides
AU2013336646B2 (en) 2012-10-25 2016-07-14 Affibody Ab ABD binding polypeptide
JP6396303B2 (ja) * 2012-10-25 2018-09-26 アフィボディ・アーベー アルブミン結合を含有するタンパク質の分離方法
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
RU2015142437A (ru) 2013-03-14 2017-04-27 Дайити Санкио Ко., Лтд Новые связывающие белки для pcsk9
US10093921B2 (en) 2013-03-14 2018-10-09 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
MX366425B (es) 2013-03-15 2019-07-04 Affibody Ab Nuevos polipeptidos.
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
SI3038633T1 (sl) 2013-08-28 2021-05-31 Ipc Research, Llc Stabilni polipeptidi, vezani na humani komplement C5
PL3039033T3 (pl) 2013-08-28 2020-01-31 Affibody Ab Polipeptydy wiążące o zmutowanym rusztowaniu
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PL3193930T3 (pl) 2014-09-17 2019-12-31 Affibody Ab Nowe polipeptydy
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
UA121973C2 (uk) 2014-10-31 2020-08-25 Нджм Біофармасьютікалз, Інк. Комплекс, що має активність фактора диференціації росту 15 (gdf15), та способи лікування ним ожиріння та гіперглікемії у суб'єкта
MY188784A (en) 2015-01-12 2021-12-31 Affibody Ab Il-17a-binding polypeptides
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
CN110023326A (zh) 2016-09-23 2019-07-16 杜克大学 具有lcst行为的非结构化无重复多肽
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
EP3665202A1 (en) 2017-08-09 2020-06-17 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
EP3691693A4 (en) 2017-10-06 2021-08-25 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
WO2019147954A1 (en) * 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) * 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
JP2022521428A (ja) 2019-02-25 2022-04-07 ザ・ユニバーシティ・オブ・シカゴ 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
WO2020245171A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
AU2021405360A1 (en) 2020-12-21 2023-06-22 Affibody Ab New polypeptide
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
CN118632866A (zh) 2022-02-08 2024-09-10 阿菲博迪公司 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
CN121038816A (zh) 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025158010A1 (en) 2024-01-25 2025-07-31 Affibody Ab Her2-binding polypeptide
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
EP1732613A2 (en) * 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
US7892827B2 (en) * 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
DE08786222T1 (de) * 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド

Also Published As

Publication number Publication date
EP2190863A2 (en) 2010-06-02
AU2008281913A1 (en) 2009-02-05
CN101765608A (zh) 2010-06-30
DE08786222T1 (de) 2010-11-25
US20150158916A1 (en) 2015-06-11
EP2190863B1 (en) 2015-09-02
AU2008281913B2 (en) 2013-11-07
HK1211040A1 (en) 2016-05-13
ES2346178T1 (es) 2010-10-13
EP2546261A2 (en) 2013-01-16
JP2010534486A (ja) 2010-11-11
WO2009016043A3 (en) 2009-06-04
CN104710518A (zh) 2015-06-17
US10118949B2 (en) 2018-11-06
US8937153B2 (en) 2015-01-20
JP5718638B2 (ja) 2015-05-13
CA2694139A1 (en) 2009-02-05
US20100273979A1 (en) 2010-10-28
DK2190863T3 (en) 2015-11-30
CN101765608B (zh) 2015-03-11
WO2009016043A2 (en) 2009-02-05
CA2694139C (en) 2018-06-05
EP2546261A3 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
ES2346178T3 (es) Nuevas composiciones, procedimientos y usos de unión de la albúmina
ES2981441T3 (es) Proteínas de repetición diseñadas que se unen a la seroalbúmina
ES2880336T3 (es) Métodos y productos para la síntesis de proteínas de fusión
ES2306794T3 (es) Moleculas de autoensamblaje.
JP6590695B2 (ja) アルブミン結合ポリペプチド
EP2161278B1 (en) Single-chain coiled coil scaffold
NZ718153A (en) Stable polypeptides binding to human complement c5
WO2024084203A1 (en) Single domain antibodies binding to albumin
ES2674983T3 (es) Método para la separación de proteínas que contienen un dominio que se une a albúmina
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
CA3241337A1 (en) Polypeptide as carrier for intestinal barrier crossing
HK40059771A (en) Designed repeat proteins binding to serum albumin
WO2025146491A1 (en) Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK40012160A (en) Designed repeat proteins binding to serum albumin
HK1189386A (en) Designed repeat proteins binding to serum albumin
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano